Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3
Authors
Thomas Fischer,
Richard StoneDaniel DeAngelo,
Ilene Galinsky,
Elihu Estey,
Carlo Lanza,
Edward Fox,
Gerhard Ehninger,
Eric Feldman,
Gary Schiller,
Virginia Klimek,
Stephen Nimer,
D. Gilliland,
Catherine Dutreix,
Alice Huntsman-Labed,
J. Virkus +14 authors
,
Francis Giles Tip Tip